Omni Bio Pharmaceutical, Inc. is a US-based biopharmaceutical company that specializes in researching and developing new applications for Alpha-1 antitrypsin (AAT). AAT is a protein derived from human blood and has been used to treat emphysema. The company was evaluating the potential of AAT for treating diseases such as Type 1 diabetes, HIV, graft versus host disease (GVHD), influenza, and others. Unfortunately, in 2015, Omni Bio Pharmaceutical, Inc. had to shut down due to difficulties in raising funds and finding licensing partners.